Small Interfering RNA Drug Class List

Drugs in Drug Class: Small Interfering RNA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y

Market Dynamics and Patent Landscape for Small Interfering RNA (siRNA) Drugs: Exclusivity, Orange Book Status, Litigation Risk, and Generic/Biosimilar Entry Barriers

Last updated: June 20, 2026

Small interfering RNA (siRNA) therapeutics have limited “generic” pathways under the Hatch-Waxman framework because they are sequence-specific biologically active products, typically protected by dense patent estates spanning the guide RNA sequence, chemical modifications, delivery lipids, conjugates (including GalNAc), formulation, and manufacturing. Commercial risk is tied to patent scope and delivery-platform coverage more than to active-sequence alone.

Snapshot: why siRNA patenting is different

• Core exclusivity drivers are often composition-of-matter claims on the RNA (sequence and chemical structure), delivery technology (lipid nanoparticles or conjugates), and manufacturing/process claims.
• “Generic” siRNA is rarely a true copy. Product sameness hinges on sequence identity, chemistry of the sense/passenger strands, conjugate chemistry, and delivery particle attributes.
• FDA regulatory classification is typically “new molecular entity”-like for each sequence/product, with no established therapeutic-equivalent interchangeability for most competing siRNA products.

---

What patents protect small interfering RNA (siRNA) drugs and their delivery systems?

Which IP layers dominate siRNA patent estates

Patent families for siRNA products commonly cluster into 6 layers:

1. Guide RNA sequence and structural claims

   • Claim scope can cover exact sequences and close variants depending on how broadly the patent is drafted.
   • Chemical modifications (2’-O-methyl, phosphorothioate, etc.) and terminal motifs often shift claims from “sequence-only” to “sequence + chemistry.”

2. Passenger strand and duplex design

   • Patents often cover duplex pairing, strand selection rules, and thermodynamic asymmetry.
   • Many estates claim both strands as components of a defined duplex reagent.

3. Delivery platform

   • Lipid nanoparticles (LNPs): patented ionizable lipids, helper lipids, PEG-lipids, and formulation ratios, plus manufacturing parameters affecting particle size and encapsulation efficiency.
   • Conjugates: for example, GalNAc targeting often maps to linker chemistry, ligand presentation, and conjugation site strategy.

4. Formulation and device-adjacent aspects

   • Encapsulation parameters, lyophilization, stabilization, buffers, and administration-related constraints.
   • For subcutaneous siRNA conjugates, formulation and concentration claims can be significant.

5. Manufacturing processes

   • Controlled mixing, microfluidic parameters, purification steps, and in-process controls that yield consistent particle attributes.

6. Method-of-use and dosing regimens

   • Label-driven method claims for patient populations, biomarker endpoints, and dosing schedules.
   • These claims can matter even if the active ingredient is challenged.

How many patents cover a typical siRNA product?

A practical rule in enforcement is that a single marketed siRNA can be supported by:

• Dozens to over 100 patent publications across multiple families.
• Multi-jurisdiction coverage (US, EP, JP, WO).
• A distribution heavily weighted toward delivery and manufacturing, not just the sequence.

This IP stacking increases the number of barriers to launch for any “copycat” product.

---

What is the Orange Book status of siRNA drugs, and how does it affect generic entry?

siRNA drugs are commonly regulated as new drug products and listed in FDA’s Orange Book if they are small-molecule/biologic analogs eligible for Hatch-Waxman listing rules. In practice for siRNA, three commercial realities dominate:

1. Orange Book is often not a sufficient “generic roadmap”

   • Even where products appear, the claim set may include classes that do not map cleanly to generic “ANDA” entry.
   • Delivery, formulation, and manufacturing claims complicate a “same as” argument.

2. Equivalence is technically fragile

   • Small differences in particle attributes or conjugate chemistry can change biodistribution and efficacy.
   • Patent claims can be drafted to capture specific physicochemical ranges.

3. Non-bioequivalent design space can still trigger infringement

   • Route changes (SC vs IV), dose form, or delivery platform can still overlap with broad composition or process claims.

---

When does siRNA exclusivity expire, and what timelines govern market lock?

siRNA exclusivity is layered:

• Patent expiration (utility and sometimes formulation or process patents).
• Regulatory exclusivity (drug-specific exclusivity windows tied to approval category, plus any pediatric exclusivity extensions).
• Orphan drug exclusivity if applicable.
• Data exclusivity and patent term adjustments in the US can extend commercial hold beyond bare patent end dates.

Key timing mechanics for investors

• The effective launch date is the last-to-expire meaningful claim that blocks a credible design-around.
• For delivery-platform-heavy estates, the last expiration can be far later than the first composition claims.
• For method-of-use estates, expiration may not end blocking if composition or process claims remain.

Typical patterns in siRNA

• Early patents often cover the sequence and core duplex chemistry.
• Later patents frequently improve delivery, stability, manufacturability, and formulation, creating staggered expiration cliffs.

---

What Paragraph IV challenges exist for siRNA drugs, and what litigation outcomes matter most?

Why Paragraph IV filings are strategically harder in siRNA

Paragraph IV is designed around Hatch-Waxman comparisons for small molecules and certain classes of biologics. For siRNA:

• The “generic” concept is less standardized.
• The candidate product must match or design around sequence, chemistry, delivery, and manufacturing.
• Infringement analysis often turns on technical equivalence (particle attributes, encapsulation, conjugate density) that drives expert discovery.

Litigation themes that recur

• Infringement disputes focus on guide strand identity, chemical modifications, duplex formation, and delivery nanoparticle composition.
• Validity disputes target obviousness (prior art LNP formulations, siRNA chemistry, targeting ligands) and written description enablement for claimed ranges.
• Courts often require detailed claim construction and expert testimony on formulation attributes.

Business impact

• The highest-risk delay is not the initial filing but the time required to prove a defensible non-infringing design, especially where patents cover a formulation “range” rather than a single recipe.

---

What is the biosimilar risk for siRNA, and is there a biosimilar pathway?

siRNA products are usually not regulated through the biologics pathway in a way that creates a “biosimilar” concept analogous to monoclonal antibodies.

Practical outcome:

• “Biosimilar-style” entry is uncommon for siRNA.
• Competitors typically pursue new drug applications or alternative routes when feasible.
• Infringement is still analyzed under patent law, not under biosimilar statutory comparability concepts.

Risk profile:

• Patent-based blocking remains the central barrier, not interchangeability doctrine.

---

How do siRNA patents compare with mRNA and antisense oligonucleotide (ASO) patent landscapes?

siRNA vs ASO

• ASO patents also stack heavily (chemistry, sequence, delivery, conjugates).
• siRNA adds duplex design constraints plus delivery particle requirements tightly coupled to RNA strand processing.

siRNA vs mRNA

• mRNA estates often center on nucleoside chemistry, sequence design, and delivery lipid systems.
• siRNA uniquely requires duplex and guide strand selection design plus a tailored delivery route to hepatic or extrahepatic tissues depending on conjugate/LNP.

Common ground

All three modalities:

• Rely on delivery and manufacturing IP.
• Use broad composition and process claims to extend enforcement.

---

Which companies hold the strongest siRNA patent estates in key therapeutic areas?

Competitive strength in siRNA typically tracks:

• Breadth of delivery-platform claims (LNP or conjugates).
• Depth of sequence coverage across multiple targets.
• Staggered continuation filings expanding formulation and manufacturing improvements.

Commercial concentration

Market share concentrates around a small number of platforms:

• GalNAc-conjugated hepatocyte-targeting siRNA platform holders.
• LNP-based systemic delivery platform holders.

A competitor’s launch odds depend on whether its target program shares a platform with the incumbent or competes at the same delivery layer.

---

What formulations are protected by siRNA patents, and which design changes are most difficult?

Formulation claim hotspots

• LNP size distribution and polydispersity specifications
• Ionizable lipid pKa-related formulation design claims
• PEG-lipid molar ratio and shielding behavior
• Encapsulation efficiency and RNA-lipid association parameters
• Stabilization buffers and lyophilization process steps
• SC formulation concentration, excipient system, and pH windows

Design-around risk

The hardest work is often not the RNA sequence but achieving:

• Equivalent tissue distribution
• Equivalent endosomal release behavior
• Equivalent potency and duration

These are the attributes that formulation claims and enabling disclosure support.

---

How does method-of-use patent coverage affect dosing and label scope for siRNA drugs?

Method-of-use patents can extend leverage beyond composition:

• Claims can cover patient subsets defined by biomarker levels or comorbidities.
• Claims can cover dosing titration regimes.
• Claims can cover duration endpoints (e.g., “maintains suppression for X weeks”).

If composition claims expire first, method-of-use claims can still block a launch if the competitor targets the same label population.

---

What patent litigation affects siRNA manufacturers, and how do settlements shape market entry?

Settlement mechanics in RNA therapeutics

Settlements often define:

• Timing windows for generic/competitor entry (carve-outs by territory or indication)
• License scope for specific targets and/or delivery platforms
• Royalty structures linked to revenue

For market dynamics, settlement terms act like de facto exclusivity extensions, even when some patents expire earlier than the settlement-defined entry.

Where settlements matter most

• When the incumbent’s claims are strong on delivery and manufacturing, settlements may license those layers.
• If only sequence claims are weak, disputes can still end in licensing because the delivery layer keeps infringement risk high.

---

What generic entry risks exist for siRNA drugs, and what “product sameness” tests are likely?

Generic entry risk is less about identical sequence and more about:

• Whether the candidate infringes by having the same guide strand sequence and modifications
• Whether the delivery system falls inside the claim scope, including particle attributes
• Whether manufacturing steps fall within process claims

Courts will rely on:

• Claim construction for “sequence,” “chemical structure,” and delivery component definitions
• Empirical testing linking product attributes to claimed ranges
• Expert testimony on formulation equivalence and potency

---

How does market dynamics evolve after siRNA patent cliffs?

When patents end:

• Competitors may launch quickly if they have independent delivery technology and manufacturing IP.
• If they rely on platform components still under patent, they face delayed entry or licensing costs.

Post-cliff patterns:

• Price competition is often slower than in small molecules because switching requires trust in delivery potency and safety.
• Payers may adopt step therapy or limited formularies, affecting uptake pace even after legal barriers fall.

---

Timeline view: how to map siRNA exclusivity cliffs

Because this analysis is modality-level rather than drug-specific, the most actionable framework is to build a timeline per product with:

1. Filing date and earliest priority
2. Utility patent grant schedule and expected expiry
3. Any patent term adjustment data points
4. Regulatory exclusivity (drug-specific, orphan, pediatric)
5. Litigation and settlement entry dates

In siRNA, the practical “go-live” date aligns with the last enforceable claim across sequence, delivery, and manufacturing families.

---

Key Takeaways

• siRNA patent estates are dense because they cover sequence and duplex design plus delivery platform, formulation, and manufacturing.
• Orange Book and Hatch-Waxman tools are not a reliable predictor of easy generic entry for siRNA because technical equivalence and claim scope extend beyond the active sequence.
• Effective market exclusivity usually ends at the last-to-expire enforceable claim tied to delivery and manufacturing.
• Paragraph IV and “generic” filings are higher-friction because design-around must clear sequence, chemistry, delivery attributes, and process patents.
• Litigation leverage frequently comes from delivery-platform breadth and formulation/process claims, which settlements can monetize through licensing and entry timing.

---

FAQs

1) Are siRNA products considered small molecules for generic purposes?
No. siRNA therapies are typically treated as discrete drug products with composition and delivery-dependent patent coverage that does not map cleanly to classic small-molecule generic entry logic.

2) Can a competitor launch a different siRNA sequence against the same target after key patents expire?
Possibly, but infringement risk can persist via method-of-use, delivery platform, and manufacturing claims that still cover the competitor’s product class and dosing approach.

3) Do delivery-platform patents block even when the guide RNA sequence is changed?
Yes. Many estates claim delivery components, formulations, and process parameters that remain relevant even for altered sequences if the same delivery approach is used.

4) What is the biggest reason siRNA generics take longer to develop than expected?
Achieving equivalent delivery behavior and potency while remaining non-infringing on formulation and manufacturing claim scope.

5) How do settlement agreements change the real timing of competitor entry?
Settlements can function as contract-based exclusivity by defining entry dates, licensed activities, and territory or indication-specific carve-outs, regardless of individual patent expiry dates.

---

References (APA)

1. FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data
3. USPTO. (n.d.). Patent Public Search. United States Patent and Trademark Office. https://ppubs.uspto.gov/
4. World Intellectual Property Organization. (n.d.). PATENTSCOPE. https://patentscope.wipo.int/